Incyte Corp at Goldman Sachs Healthcare C-Suite Unscripted Conference Transcript
Thank you for joining us. And with Herve on stage is Matt Dellatorre, who's been following the story for a very long time. To start here, Herve, a big picture question. Product diversification continues to be a key focus for Incyte. And as we stand today with Jakafi and Opzelura, and the current pipeline, notably, where you do have some later-stage assets such as Povorcitinib and axatilimab or outlook for the business and growth in 2024 and longer term?
Questions & Answers
Good. No. I mean to see you. I was hoping to be able to blame you for infecting everybody at JPM next week. But somebody will have to be blamed. So that will be funny. Okay. Speaking about Incyte. I mean that is '24 is obviously starting. So now we are more or less seeing what's going to happen in some of the big events. And the long term is where there are a lot of interesting perspective.
I must maybe step back for a 1/10 of a minute here to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
